Gemcitabine
- Generic Name
- Gemcitabine
- Brand Names
- Gemzar
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11F2N3O4
- CAS Number
- 95058-81-4
- Unique Ingredient Identifier
- B76N6SBZ8R
- Background
Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...
- Indication
Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.
In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...
- Associated Conditions
- Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma
- Associated Therapies
- -
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 87
- Registration Number
- NCT06532331
- Locations
- 🇯🇵
Aichi Cancer Center, Nagoya-shi, Aichi, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
🇯🇵Kanazawa University Hospital, Kanazawa-shi, Ishikawa, Japan
A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 68
- Registration Number
- NCT06528093
- Locations
- 🇧🇪
Brussels - UNIV Saint-Luc, Bruxelles, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
🇫🇷CTR Leon Berard, Lyon, France
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
- Conditions
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- SecuraBio
- Target Recruit Count
- 124
- Registration Number
- NCT06522737
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 244
- Registration Number
- NCT06521255
- Locations
- 🇨🇳
Xinjiang Medical University Affiliated Cancer Hospital, Urumqi, China
🇨🇳Henan Cancer Hospital, Zhengzhou, China
🇨🇳Beijing Hospital, Beijing, China
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Target Recruit Count
- 350
- Registration Number
- NCT06519370
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Harbin Medical University
- Target Recruit Count
- 132
- Registration Number
- NCT06513455
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 360
- Registration Number
- NCT06508658
- Locations
- 🇦🇺
Toowoomba Hospital /ID# 263243, Toowoomba, Queensland, Australia
🇧🇪Universitair Ziekenhuis Brussel /ID# 242574, Jette, Bruxelles-Capitale, Belgium
🇧🇪AZ-Delta /ID# 264740, Roeselare, West-Vlaanderen, Belgium
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT06498648
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Vasgene Therapeutics, Inc
- Target Recruit Count
- 700
- Registration Number
- NCT06493552
Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 36
- Registration Number
- NCT06491472
- Locations
- 🇨🇳
Wuhan Union Hospital of China, Wuhan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.